Aynur Unalp-Arida

Aynur Unalp-Arida

Contact Information

615 North Wolfe Street, Room W5010
Baltimore , Maryland   21205
US        

410-614-4851
410-955-0932

Overview

Current projects include: Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) to conduct clinical trials, epidemiological, and therapeutic research in patients with nonalcoholic fatty liver disease (NAFLD) and NASH The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial (FLINT) NCT01265498  Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children (CyNCh) NCT01529268 Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 NCT01030484 NAFLD Pediatric Database 2 NCT01061684 Gastroparesis Consortium (GpCRC) to conduct clinical trials, epidemiological, and therapeutic research for the management of gastroparesis and similar functional disorders Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial (APRON) NCT01149369 Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG) NCT01030341 Gastroparesis Registry 2 (GpR 2) NCT01696747

Honors and Awards

Doctoral Fellowship, 1994-1999, The Turkish Higher Education Council Postdoctoral Training Grant, 1999-2000, The Johns Hopkins Center for Clinical Trials

Research Interests

epidemiology, clinical trials, regulatory science, safety monitoring nonalcoholic steatohepatitic (NASH), nonalcoholic fatty liver disease (NAFLD), gastroparesis

Publications

Most recent publications

  • Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Liver Int. 2013 Nov 5. doi: 10.1111/liv.12379. 
  • Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology. 2012 Sep;56(3):943-51. doi: 10.1002/hep.25772.
  • Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A, Diehl AM; NASH CRN. Hepatology. 2012 Jun;55(6):1711-21. doi: 10.1002/hep.25559.
  • Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520
  • Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929.